Project Grant R01CA318433
Award Date 8/6/26
Completion Date 7/31/31
Dollars Obligated $708K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $153,330 on August 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to develop a radiotheranostic platform targeting androgen receptor in prostate cancer. The funded work develops non-steroidal androgen receptor agonists for DNA-targeted Auger electron therapy to address treatment-resistant prostate cancer. The project combines disease monitoring and targeted cytotoxic agent delivery using...
- The National Cancer Institute, a component of the Department of Health and Human Services, awarded $644,423 to Sloan-Kettering Institute for Cancer Research on June 18, 2026, under the Cancer Treatment Research program (CFDA 93.395). The recipient will develop short-wave infrared (SWIR) Cerenkov luminescence imaging (SWIR-CLI) to visualize the distribution of therapeutic radiotracers and improve monitoring of targeted radiotherapy. Current Cerenkov luminescence imaging requires light-tight...
- The National Cancer Institute awarded Molecular Targeting Technologies, Inc. $637,529 on August 24, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop targeted radionuclide therapy for non-small cell lung cancer using Lu-177 EBRGD. The award funds research to evaluate in vivo tumor targeting, biodistribution, therapeutic efficacy, and normal tissue toxicity of 177Lu-DOTA-EB-RGD as a treatment for non-small cell lung cancer, which accounts for 80–85 percent...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $699,794 on August 25, 2026, under the Cancer Treatment Research program (CFDA 93.395) to modulate the tumor microenvironment and enhance nanoparticle delivery to cancer cells. The project addresses limited nanoparticle efficacy in cancer therapies caused by nonspecific uptake in the mononuclear phagocyte system and interception by tumor-resident macrophages, which results in median tumor uptake of under 1...
- The National Cancer Institute awarded The Regents of the University of California, San Francisco $575,178 on May 15, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop radiopharmaceuticals termed "restricted interaction peptides" (RIPs) targeting human kallikrein 2 for molecularly targeted radiotherapy of metastatic castration-resistant prostate cancer. The project tests whether RIPs—low molecular weight peptides internally cleaved by tumor...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $1,467,021 on April 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate tumor regenerative cell populations and develop L1CAM-targeted antibody-drug conjugates that may overcome resistance to neoadjuvant therapy in locally advanced rectal cancer. The project will use genomic and transcriptomic analysis of pre-treatment rectal tumors, mechanistic studies in patient-derived organoid...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $577,331 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to repurpose HSP90 inhibitors as a condensate-directed therapy for receptor tyrosine kinase fusion-driven cancers. The project targets cancers driven by RTK fusions such as EML4-ALK and CCDC6-RET, which account for 3–5 percent of all cancer diagnoses and approximately 225,000 new lung cancer patients annually worldwide. The...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $709,145 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and evaluate senescence-modulating nanoparticles targeting P-selectin on senescent cells as a strategy to potentiate cancer immunotherapy in fibrotic tumors. The project addresses a barrier in cancer immunotherapy: many patients with solid tumors remain unresponsive to immune checkpoint blockade and CAR T cell...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $444,590 on June 2, 2026, under the Cancer Treatment Research program (CFDA 93.395) to evaluate genetic and epigenetic determinants of treatment response in patients with accelerated and blast phase myeloproliferative neoplasms. The research builds on a prior Phase I/II study (MPD-RC 109) testing combination therapy with the JAK1/2 inhibitor ruxolitinib and the hypomethylating agent decitabine in advanced MPN...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $676,849 on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to enhance MIRDSOFT.ORG, an open-source radiation dosimetry platform operated by the MIRD Committee of the Society of Nuclear Medicine and Molecular Imaging. The award funds development of computational human phantoms and dosimetry software to support personalized dose estimation in nuclear medicine and radiology. Deliverables...